DO STATINS INCREASE BLEEDING RISK IN ANTICOAGULATED INDIVIDUALS?  by Roumia, Mazen et al.
Prevention
A1440
JACC March 17, 2015
Volume 65, Issue 10S
Do statins incRease bleeDing Risk in anticoagulateD inDiviDuals?
Poster Contributions
Poster Hall B1
Sunday, March 15, 2015, 9:45 a.m.-10:30 a.m.
Session Title: Statins, Cholesterol Guidelines and Lifestyle
Abstract Category: 21.  Prevention: Clinical
Presentation Number: 1178-108
Authors: Mazen Roumia, Peter Berger, Michael Evans, Steven Steinhubl, Geisinger Health System, Danville, PA, USA
background: Experimental and clinical studies suggest that statins may have direct anticoagulant and antiplatelet properties unrelated to 
their lipid-lowering effect. The goal of this study was to examine the impact of statins on the risk of bleeding when used concomitantly with 
warfarin.
Methods: We performed a retrospective analysis of Geisinger Health System’s electronic health records of patients with atrial fibrillation 
anticoagulated with warfarin and followed by our Outpatient Anticoagulation Clinic, run by PharmDs, between 01/01/00 and 05/15/13. 
13,179 patients were identified of whom 8,395 patients were concomitantly being treated with statins for primary or secondary 
cardiovascular prevention. 4,784 patients did not receive any statins during the warfarin treatment period. The primary end point was 
bleeding resulting in hospital admission or discontinuation of warfarin.
Results: The 13,179 patients had a mean follow-up of 7.6 years, representing 101,322 patient years of observation. 1,028 patients had 
a primary end point during the study period. 749 patients on statins had bled (8.92%) with 1,154 cases of bleeding and an event rate of 
13.75%. In the group not on a statin, we identified 279 patients who bled (5.83%) with 425 cases of bleeding and a bleeding event rate of 
8.89%. The rate of bleeding events was significantly higher in patients taking warfarin and statins than those taking warfarin alone (13.75% 
vs 8.89%, P <0.05). The difference was also significant when the number of individual patients with bleeds were compared (8.92% vs 
5.83%, P value < 0.05).
conclusion:  The concomitant use of statins with warfarin is associated with a higher risk of bleeding than warfarin alone. Statins possess 
potentially unique antithrombotic properties that may offer a new therapeutic strategy. Whether this is due to an antiplatelet mechanism, 
and whether this observation ought to influence patient management, require further study.
